The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).
 
Ian W. Flinn
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Century Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); Great Point Partners (Inst); Hutchison MediPharma (Inst); Iksuda Therapeutics (Inst); Innocare (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Novartis (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Shanghai Yingli Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Path Holdings, Inc (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CALIBR (Inst); Celgene (Inst); City of Hope (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Curis (Inst); Fate Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Loxo (Inst); Merck (Inst); Millennium (Inst); MorphoSys (Inst); Myeloid Therapeutics (Inst); Novartis (Inst); Nurix (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Rhizen Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TCR2 Therapeutics (Inst); Tessa Therapeutics (Inst); TG Therapeutics (Inst); Triact Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
 
Caron Alyce Jacobson
Honoraria - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instil Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Consulting or Advisory Role - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instil Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Research Funding - Kite, a Gilead company; Pfizer
 
Loretta J. Nastoupil
Honoraria - ADC Therapeutics; Bristol-Myers Squibb; Caribou Biosciences; Epizyme; Genentech/Roche; Genmab; Gilead Sciences; Janssen Oncology; Morphosys; Novartis; Takeda; TG Therapeutics
Consulting or Advisory Role - Interius Biotherapeutics; SIRPant Immunotherapeutics
Research Funding - Allogene Therapeutics; Bristol-Myers Squibb/Celgene; Caribou Biosciences; Epizyme; Genentech/Roche; Gilead Sciences; IgM Biosciences; Janssen Biotech; Novartis; Takeda
Travel, Accommodations, Expenses - Genentech/Roche
 
Franck Morschhauser
Honoraria - Chugai/Roche; Eisai; Roche/Genentech
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; epizyme; Genmab; Gilead Sciences; Novartis; Roche/Genentech; SERVIER
 
Andrew Davies
Honoraria - AbbVie; AstraZeneca; Bristol-Myers Squibb; Genmab; Incyte; Kite, a Gilead Company; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; Genmab; Kite, a Gilead Company; Roche
Research Funding - AstraZeneca; Cellcentric; MSD; Roche
Travel, Accommodations, Expenses - Roche
 
Christian Buske
Honoraria - Abbvie; Bayer; Beigene; Celltrion; Gilead Sciences; Hexal; Janssen; MorphoSys; Novartis; Pfizer; Regeneron; Roche/Genentech; Sobi
Consulting or Advisory Role - Abbvie; Bayer; Beigene; Celltrion; Gilead Sciences; Janssen; MorphoSys; Novartis; Pfizer; Regeneron; Roche
Speakers' Bureau - Abbvie; Bayer; BeiGene; Celltrion; Gilead Sciences; Hexal; Janssen; MorphoSys; Novartis; Pfizer; Regeneron; Roche; Sobi
Research Funding - Amgen; Bayer (Inst); Celltrion; Janssen; MSD; Roche/Genentech
 
Paolo Corradini
Honoraria - Abbvie; ADC Therapeutics; Amgen; BeiGene; Celgene; Daiichi Sankyo Pharmaceutical; GlaxoSmithKline; Incyte; Janssen; Kite, a Gilead Company; Kyowa Kirin; Lilly O.; Nerviano Medical Sciences; Novartis; Roche; Sanofi; SOBI; Takeda
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Amgen; BeiGene; Celgene; Daiichi Sankyo Pharmaceutical; GlaxoSmithKline; Incyte; Janssen; Kite, a Gilead Company; Kyowa Kirin; Lilly O.; Nerviano Medical Sciences; Novartis; Roche; Sanofi; SOBI; Takeda
Travel, Accommodations, Expenses - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; Janssen; Kite, a Gilead Company; Novartis; Roche; Takeda
 
Armando López Guillermo
Honoraria - Roche
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; Incyte; Janssen; Kern Pharma; Kite/Gilead; Pfizer; Roche; Takeda
Research Funding - Celgene/Bristol-Myers Squibb; Janssen; Roche
Travel, Accommodations, Expenses - Kite/Gilead; Roche
 
Ran Reshef
Consulting or Advisory Role - Atara Biotherapeutics; Capstan Therapeutics; Gilead Sciences; Incyte; Instil Bio; Jasper Therapeutics; Midatech Pharma; Orca Bio; Regeneron; Synthekine; Takeda; TScan Therapeutics
Research Funding - Abbvie (Inst); Atara Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); CareDX (Inst); Gilead Sciences (Inst); immatics (Inst); Incyte (Inst); Janssen (Inst); Precision Biosciences (Inst); Sanofi (Inst); Synthekine (Inst); Takeda (Inst); TCR2 Therapeutics (Inst)
Expert Testimony - Bayer
Travel, Accommodations, Expenses - Gilead Sciences; Instil Bio
 
Vinod Parameswaran
No Relationships to Disclose
 
Alison Sehgal
Speakers' Bureau - OncLive; Peerview
Research Funding - Juno Therapeutics; Kite/Gilead; Miltenyi Biotec
 
Michael Timothy Tees
No Relationships to Disclose
 
Christine Lui
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Kite, a Gilead Company
Travel, Accommodations, Expenses - Kite, a Gilead Company
 
Wei Xue
Employment - Biogen; Kite, a Gilead Company
Stock and Other Ownership Interests - Biogen; Kite, a Gilead Company
Travel, Accommodations, Expenses - Kite, a Gilead Company
 
Sara Beygi
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Kite, a Gilead Company
Travel, Accommodations, Expenses - Kite, a Gilead Company
 
Nikolay Grechko
Employment - Clovis Oncology; Kite, a Gilead Company
Stock and Other Ownership Interests - Clovis Oncology; Kite, a Gilead Company
Travel, Accommodations, Expenses - Clovis Oncology; Kite, a Gilead Company
 
Pisita Bolsue
Employment - Kite, a Gilead Company
Other Relationship - Kite, a Gilead Company
 
Alessandro Giovanetti
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Kite, a Gilead Company
 
Christina Ann To
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Myrna Nahas
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Kite, a Gilead Company